Treating SMA is about to get more interesting

The 2016 approval of Biogen’s Spinraza was a watershed event for patients with spinal muscular atrophy, a muscle-wasting disease for which there were previously no treatments. Three years later, those patients see a future in which they might be able to choose between Spinraza, a gene therapy, and a daily pill — or combine all three.

And we want to talk about it. Later this month, we’re hosting a call with an SMA expert who will answer all your questions about how the future of treatment might shake out.

By then, Novartis will have presented new data on its gene therapy, and Roche will have disclosed some details on its oral treatment. If both work, and Spinraza’s demonstrated benefits hold up, how will doctors decide which patients get which treatment?

If you’d like to find out, sign up here for STAT's premium service, STAT Expert Advantage.